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Obesity increases the risk of developing life-threatening metabolic
diseases including cardiovascular disease, fatty liver disease, di-
abetes, and cancer. Efforts to curb the global obesity epidemic and
its impact have proven unsuccessful in part by a limited un-
derstanding of these chronic progressive diseases. It is clear that
low-grade chronic inflammation, or metaflammation, underlies
the pathogenesis of obesity-associated type 2 diabetes and
atherosclerosis. However, the mechanisms that maintain chro-
nicity and prevent inflammatory resolution are poorly understood.
Here, we show that inhibitor of κB kinase epsilon (IKBKE) is a novel
regulator that limits chronic inflammation during metabolic dis-
ease and atherosclerosis. The pathogenic relevance of IKBKE was
indicated by the colocalization with macrophages in human and
murine tissues and in atherosclerotic plaques. Genetic ablation of
IKBKE resulted in enhanced and prolonged priming of the NLRP3
inflammasome in cultured macrophages, in hypertrophic adipose
tissue, and in livers of hypercholesterolemic mice. This altered profile
associated with enhanced acute phase response, deregulated choles-
terol metabolism, and steatoheptatitis. Restoring IKBKE only in he-
matopoietic cells was sufficient to reverse elevated inflammasome
priming and these metabolic features. In advanced atherosclerotic
plaques, loss of IKBKE and hematopoietic cell restoration altered
plaque composition. These studies reveal a new role for hematopoi-
etic IKBKE: to limit inflammasome priming and metaflammation.
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The metabolic syndrome is defined by the coexistence ofcentral obesity, deregulated carbohydrate, and lipid metab-
olism and/or hypertension. Collectively these features increase
the risk of developing type 2 diabetes, nonalcoholic fatty liver
diseases, and atherosclerosis. These metabolic diseases have
additional features in common; they are chronic disorders char-
acterized by a state of persistent inflammation and tissue
remodeling. In particular, chronic low-grade inflammation or
“metaflammation” is now established as an important causative
factor driving metabolic disease. Much progress has been made
in our understanding of how metabolic stress or overnutrition
induces metaflammation. However, the molecules involved in
maintaining chronicity of low-grade inflammation remain unclear.
As specialized mediators of host defense, macrophages express
danger-sensing pattern recognition receptors (PRRs) that include
transmembrane receptors of the Toll-like receptor/interleukin-1
receptor (TLR/IL-1R) superfamily and intracellular cytosolic
receptors such as RIG-I–like receptors and nucleotide-binding
oligomerization domain (NOD)-like receptors (1, 2). Numerous
TLR/IL-1Rs and their downstream mediators have been impli-
cated in the pathogenesis of obesity-associated diabetes (3, 4),
fatty liver disease (5, 6), and atherosclerosis (7, 8). In some cases,
putative nonmicrobial, host-derived sterile ligands have also been
identified. For example, TLR4 is a putative sensor for dietary
saturated fatty acids (SFAs) (4, 9) and TLR2 together with CD36
recognize oxidized low-density lipoproteins (OxLDL) (10). Re-
cently, the NOD-like receptor NLRP3 has also been implicated in
the pathogenesis of metabolic disease (11, 12) and atherosclerosis
(13, 14). NLRP3 senses intracellular defects such as oxidative
stress, ER stress, impaired mitophagy, impaired autophagy, or
lysosome dysfunction, and responds by assembling the NLRP3
inflammasome and activating caspase-1. Active caspase-1 pro-
motes both the proteolytic maturation of proinflammatory inter-
leukins (IL)-1β and IL-18, and inactivation of antiinflammatory IL-
33. Caspase-1 activity is also linked to the release of alarmins (15,
16) and excessive activation to pyroptotic cell death (17).
Stimulation of NLRP3-dependent inflammation is established
as a “two-step” process. The first is a priming step that involves
TLR/NFκB-mediated induction of NLRP3 and pro–IL-1β
mRNA. The second step promotes NLRP3 inflammasome as-
sembly and activity through additional stress-related signals. In
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contrast, the mechanism that maintains chronicity of inflamma-
some activity is not known. Here, we identify a new modulator
of inflammasome priming and chronic inflammation: the in-
hibitor of κB kinase epsilon (IKBKE, IKKe, or IKKi). IKBKE
is best characterized for its role in type 1 antiviral responses
downstream of TLR4, TLR3/TRIF-dependent or MAVS-depen-
dent signals (18–21). However, aberrant induction of IKBKE
has also been linked to oncogenic signals (22) and in regulating
energy balance in murine models of obesity (23, 24). This latter
role remains incompletely understood because contrasting
effects on weight gain have also been reported (25). Importantly,
the clinical relevance of IKBKE induction has not been de-
termined in human disease, nor has the role of hematopoietic
IKBKE in metaflammation. Since IKBKE is predominantly
expressed in immune cells, mediates TLR signals, and is a known
NFκB target gene, we hypothesize that IKBKE is induced in
parallel with inflammasome priming transcripts and as such is
a good candidate to mediate inducible counterregulation of im-
mune activity during chronic inflammation. As a regulator of in-
flammatory tone, IKBKE would be required to limit inflammation
in a context and time-dependent manner. Herein, we report that
IKBKE is required to temporally limit NLRP3 inflammasome
priming in macrophages. Furthermore, we demonstrate that IKBKE
expression associates with the pathogenesis of metabolic disease
in humans where it colocalizes with proinflammatory macro-
phages, and that hematopoietic IKBKE is sufficient to limit
metaflammation.
Results
IKBKE Associates with Clinical Pathology and Colocalizes with
Proinflammatory Tissue Macrophages. To explore the relevance
of IKBKE in clinical pathology, we first examined its expression
in three tissues commonly associated with metaflammation and
dyslipidemia: adipose tissue, liver and vasculature. In human
adipose tissue, IKBKE mRNA correlated positively with body
mass index (Fig. 1A) and was induced in two murine models of
obesity (Fig. S1 A and B). Adipose Ikbke also associated with
increased macrophage and inflammatory markers (Fig. S1 A and
B). It was elevated in macrophage-enriched CD11+ fractions, and
this induction preceded the increase in adipocytes from obese tis-
sues (Fig. 1B). Adipose Ikbke was also reduced by antiinflammatory
thiazolidione treatment (Fig. S1C). In obese subjects with non-
alcoholic steatohepatitis (NASH), hepatic IKBKE was significantly
induced and correlated positively with expression of the macro-
phage marker CD68 (Fig. 1 C and D, Table 1, and Table S1).
Furthermore, hepatic IKBKE expression correlated strongly with
expression of multiple inflammatory genes and indicators of he-
patic dysfunction (Table 1). In the vasculature, where chronic
inflammation promotes atherosclerosis, IKBKE was readily
detected in human atherosclerotic plaques and also in advanced
plaques from proatherogenic, apolipoprotein E-deficient (Apoe−/−)
mice (Fig. 1 E and F). Double labeling indicated that IKBKE
colocalized primarily with infiltrating macrophages and not with
SMA+ vascular smooth muscle cells (Fig. 1 E and F). These
findings indicate that IKBKE is located in three pathologically
relevant, anatomical locations where it is closely associated with
macrophage infiltration and chronic inflammation.
IKBKE Is Induced in Proinflammatory Macrophages and Its Ablation
Prolongs NLRP3 Inflammasome Priming. To investigate the in-
volvement of IKBKE in inflammatory macrophages, we per-
formed temporal profiling of IKBKE expression in stimulated
macrophages. Classic proinflammatory (M1/Th1) activators ro-
bustly induced Ikbke expression within 4 h (Fig. 1G). Although this
induction was transient, Ikbke levels remained significantly ele-
vated for up to 24 h. This increase was observed in stimulated
macrophages from both wild-type and proatherogenic Apoe−/−
mice (Fig. S1D–G). Induction of Ikbke was a common response to
stimulation by multiple proinflammatory ligands, including TNFα,
IL-1β, IFN-γ, LPS, and peptidoglycan (PGN), albeit with differing
magnitude and temporal kinetics (Fig. S1 D–G). Conversely, Ikbke
expression was inhibited by the antiinflammatory (M2a/Th2) cy-
tokine IL-4 (Fig. 1G and Fig. S1G). IL-10, an activator of M2c
macrophages, had no effect on Ikbke expression (Fig. 1G). In-
duction of Mox macrophages and foam cells by oxidized lipids
(OxPAPC) and lipoproteins (OxLDL) transiently reduced Ikbke
expression (Fig. 1G). These findings indicate that IKBKE is tem-
porally regulated by proinflammatory mediators and may be a good
candidate for cell autonomous regulation of chronic inflammation.
To investigate the requirement for IKBKE during an inflam-
matory response by proatherogenic macrophages, we first generated
bone marrow differentiated macrophages (BMDMs) from Apoe−/−
mice that also lacked IKBKE (dKO) together with wild-type IKBKE
controls (Apoe−/−). BMDMs from both genotypes appeared mor-
phologically indistinguishable and expressed similar levels of
Fig. 1. IKBKE is expressed in pathogenic tissues, colocalizes with macro-
phages, and is induced in proinflammatory macrophages. (A) IKBKE mRNA
expression in scWAT associates with human BMI. (B) Expression of Ikbke in
adipose tissue fractions from wild-type and ob/ob mice at 1 and 4 mo of age.
Adipocytes (Ad) and macrophage-enriched CD11+ve stromavascular frac-
tions (SVF) were isolated as described (33). (C and D) Hepatic IKBKE and CD68
expression in obese subjects with NAFLD and/or NASH. Adjacent sections of
a human carotid plaque (E) or aortic root plaque of an Apoe−/− mouse (F),
coimmuno-stained for IKBKE (E and F; brown), and either SMA for smooth
muscle cells (E and F, Upper; blue) or anti-CD68 (E and F, Lower; blue) or
Mac3 (F, Upper; blue) for macrophages; L, lumen. (Scale bars: 200 μm.) (G)
Expression of Ikbke in BMDMs after indicated treatments: LPS (100 ng/mL) +
IFN-γ (100 ng/mL), TNFα (10 ng/mL) + IFN-γ (100 ng/mL), IL-4 (10 ng/mL), IL-10
(10 ng/mL), OxPAPC (50 μg/mL), and OxLDL (50 μg/mL). Statistical significance
is indicated by *P < 0.05, **P < 0.01 compared with corresponding WT
fractions (B), NASH patients (C and D) or 24-h control (G) and §P < 0.05, §§P <
0.01, §§§P < 0.001 compared with 4 h control (G).





















macrophage differentiation markers (Fig. S2A). IKBKE ablation
did not alter the ability of macrophages to polarize into classical/
proinflammatory (M1) or alternative/antiinflammatory (M2) sub-
types following chronic treatment with LPS+IFN-γ or IL-4, re-
spectively (Fig. S2B). However, M1-activated macrophages lacking
IKBKE expressed significantly elevated levels of NLRP3 inflam-
masome-related transcripts. Specifically, the expression of Nlrp3 was
higher in dKO macrophages following proinflammatory stimulation,
and remained significantly greater for up to 24 h, when expression in
Apoe−/− control cells was returning back down to unstimulated levels
(Fig. 2 A and B). The expression of other NLR/PYD inflamma-
somes including Nlrp1 and Aim2 was not consistently greater in
chronically stimulated dKO macrophages (Fig. S2C), indicating an
IKBKE-dependent selectivity toward NLRP3 inflammasome prim-
ing. IKBKE-dependent enhanced Nlrp3 expression was not limited
to proatherogenic Apoe−/− macrophages because it was also ob-
served in chronically activated Ikbke−/− BMDMs from C57BL/6 and
mixed background mice (Fig. S2 D and E). The expression and in-
duction of IL1-related cytokines, Il1a, Il1b, and Il33, was more re-
stricted to specific stimuli and time-dependent. Most notably, the
induced expression of Il1b was dramatically greater in chronically
stimulated dKO macrophages (Fig. 2D and Fig. S2 D and E). The
expression of Il1a was less striking but greater in dKO macrophages
at both 4 and 24 h (Fig. S3 A and B), whereas Il33 was significantly
greater only at 4 h after stimulation (Fig. S3 C and D). Other
NLRP3 inflammasome-associated transcripts, namely Il18, Pycard,
and Casp1, did not show consistently elevated expression in dKO
macrophages (Fig. S3 E–J). Immunoblotting for both pro–IL-1β and
mature IL-1β proteins in cell lysates confirmed that, in the absence
of exogenous inflammasome activators, IKBKE ablation did not
directly alter IL-1β processing but resulted in prolonged pro–IL-1β
availability (Fig. 2E). However, in the presence of additional NLRP3
activation (by ATP, nigericin, or high-dose LPS) chronically primed
Ikbke−/− macrophages secreted greater amounts of IL-1β (Fig. 2F).
Collectively, these data indicate that IKBKE is required to limit both
the magnitude and temporal dynamics of NLRP3 inflammasome
priming in macrophages. Since the expression of endogenous
IKBKE is itself dynamically induced by the same inflammatory
stimuli in BMDMs, our data supports the notion that in wild-type
macrophages, the sustained expression of endogenous IKBKE is
required to counterregulate chronic NLRP3 inflammasome priming.
IKBKE Deficiency Enhances Inflammasome Priming in Adipose Tissue.
We next investigated the in vivo consequences of IKBKE ablation.
Since IKBKE ablation may prevent the development of high fat diet-
induced obesity and associated metaflammation, we investigated the
impact of IKBKE ablation in Apoe−/− mice. This model is protected
from diet-induced obesity but develops metaflammation in adipose
tissue, liver steatosis, hypercholesterolemia, and readily develops ath-
erosclerotic plaques (26, 27). Moreover, macrophages from these mice
can be primed for NLRP3 activity in vivo following feeding with
a high-fat, high-cholesterolWestern diet (28).We reasoned that in this
model, the absence of IKBKE would result in enhanced NLRP3
inflammasome priming and activity, which, in turn, would promote
a greater inflammatory response and exacerbated metaflammation.
To test this hypothesis, we fed Apoe−/− mice and dKO littermates
a Western-type diet (WD) for 16 wk before killing and tissue collec-
tion. Expression profiling of adipose tissue revealed that multiple
NLRP3 inflammasome-related genes, (i.e., Il1a, Il1b, Il33, Il18, P2rx7,
Nlrp3, Pycard, and Casp1) were all elevated in WD-fed female dKO
mice (Fig. 3A). Furthermore, the IL-1β–responsive IL-1 receptor an-
tagonist (Il1rn) was elevated in dKO mice, suggesting that inflam-
masome activity was enhanced. However, this observation coincided
with an increased presence and expression of the macrophage markers
Emr1, Itgam, and Itgax and the proinflammatory cytokine Tnfa (Fig. 3
B and C). This proinflammatory profile was also associated with in-
creased leptin production, adipocyte hypertrophy, white adipose tissue
(WAT) mass, and generalized diet-induced adiposity (Fig. 3 B–E and
Fig. S4 A–D), suggesting that IKBKE may also be important in reg-
ulating energy balance and subsequent obesity-related metabolic de-
regulation. Indeed, food intake but not energy expenditure was
significantly increased in female dKO mice (Fig. S5 A–C). Despite
increased adiposity, proadipogenic markers were unaltered (Fig.
S5D) and dKO mice remained euglycemic, glucose- and insulin-
tolerant (Table S2 and Fig. S5 E and F). However, elevated insulin
levels in dKO mice indicated mild systemic insulin resistance
(Table S2). In contrast to female dKO mice, male dKO mice did
not exhibit differential weight gain or adiposity following WD
feeding, nor was there evidence of increased inflammatory cell
Fig. 2. Enhanced NLRP3 inflammasome priming in macrophages lacking
IKBKE. Effect of IKBKE ablation on expression profiles of NLRP3 inflamma-
some-related genes in BMDMs following 4-h (A and C) or 24-h (B and D)
treatment with LPS (100 ng/mL), IFN-γ (100 ng/mL), PGN (50 μg/mL), TNFα
(10 ng/mL), IL-1β (10 ng/mL), IL-4 (10 ng/mL), or indicated combinations. (E)
Western blot of IKBKE, IL-1β, and α-tubulin in BMDM whole-cell lysates
collected at 24 h after treatment without NLRP3 activation. (F) IL-1β secre-
tion was determined in conditioned media from BMDMs primed with LPS
(100 ng/mL) and IFN-γ (100 ng/mL) for up to 24 h and treated with NLRP3
activators: ATP (5 mM for 1 h), Nigericin (10 μM for 1 h) or high-dose LPS
(10 μg/mL for 16 h). Statistical significance is indicted by *P < 0.05, **P <
0.01, and ***P < 0.001 relative to corresponding Apoe−/− BMDMs.
Table 1. Hepatic IKBKE expression correlates with indices of
liver dysfunction and inflammatory gene expression in obese
patients
IKBKE expression
Parameter measured rs P n
Hepatic histology
Steatosis 0.507 0.004 30
NASH 0.542 0.002 30
NAFLD activity score (NAS) 0.559 0.001 30
Plasma biochemistry
Alanine aminotransferase (ALT) 0.412 0.024 30
Aspartate transaminase (AST) 0.375 0.041 30
HOMA-IR 0.404 0.037 27
HbA1c, % 0.430 0.022 28
Hepatic gene expression
CD68 0.710 <0.001 26
IL1B 0.570 0.001 29
NLRP3 0.804 <0.001 30
CASP1 0.737 <0.001 30
CASP4 0.777 <0.001 30
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recruitment in adipose tissue (Fig. S6). Nonetheless, the expres-
sion of NLRP3 mRNA was significantly elevated and Il1a, Il1b,
and Il33 all showed trends toward increased expression (Fig. S6H).
Hematopoietic Restoration of IKBKE Limits Inflammasome Priming in
Adipose Tissue. Since the effects of global IKBKE ablation may be
due to removal of IKBKE in nonimmune cell types such as adi-
pocytes, we next sought to determine whether restoration of he-
matopoietic IKBKE was sufficient to reverse elevated NLRP3
inflammasome priming in vivo. To test this hypothesis, recipient
dKO female mice were irradiated, and reconstituted with bone
marrow (BM) from age-and sex-matched Apoe−/− mice that either
expressed endogenous wild-type IKBKE (Apoe−/− BM) or lacked
IKBKE (dKO BM). Following BM reconstitution, all chimeric mice
were fedWD for 16 wk. Transplant with Apoe−/− (Ikbke+/+) BMwas
sufficient to reduce adipose tissue expression of NLRP3-related
inflammasome genes (Fig. 3F). However, proinflammatory cyto-
kines and macrophage markers were also reduced (Fig. 3G) and
coincided with a reduction in all indicators of adiposity including,
leptin production, adipocyte hypertrophy, WAT mass, and gener-
alized adiposity (Fig. 3 G–J and Fig. S4 E–H). Indicators of energy
expenditure were not altered (Fig. S5 G and H), and the expression
of proadipogenic genes in WAT remained similar (Fig. S5I). These
mice also remained euglycemic and glucose- and insulin-tolerant
(Table S2 and Fig. S5 J and K). However, insulin levels were re-
duced by hematopoietic IKBKE reconstitution, suggesting pro-
tection from the development of mild insulin resistance (Table S2).
Hence, whereas mice transplanted with dKO bone marrow
reproduced the diet-induced increase in body weight, adiposity,
and adipose tissue inflammation, transplant with Ikbke+/+
marrow protected dKO mice from developing excessive diet-
induced obesity and also reduced inflammasome priming and
metaflammation in adipose tissue.
IKBKE Deficiency and Hematopoietic Restoration Alters Hepatic
Inflammasome Priming, APR, and Hypercholesterolemia. Since
IKBKE is induced in chronically inflamed livers, and WD-fed
Apoe−/− mice also develop hepatic steatosis, we next investigated
the impact of IKBKE ablation on hepatic NLRP3 inflammasome
expression in dKO mice. The expression of Il1a, Il1b, Il33, P2rx7,
Nlrp3, Pycard, and Casp1 were all elevated in dKO livers (Fig.
4A). This induction also coincided with increased levels of Il1rn
(Fig. 4A), proinflammatory (Th1/M1) genes, and macrophage
markers in livers of dKO mice (Fig. 4B and Fig. S7A). However,
antiinflammatory (Th2/M2) expression profiles were similar in
both genotypes (Fig. S7B). These data suggest IKBKE ablation
promotes priming and functional activation of hepatic NLRP3
inflammasomes and metaflammation.
In rodents, hepatic IL-1β production and inflammation pro-
motes a class 1 acute phase response (APR) and impairs cho-
lesterol clearance. Indeed, dKO livers expressed greater levels of
class 1 APR transcripts (Fig. 4C): serum amyloid A 1/2 (Saa1/2)
and Chemokine C-X-C motif ligand 1 (Cxcl1). Hepatic expres-
sion of the inflammation-responsive, cholesterol-clearing enzyme
Cyp7a1 was reduced (Fig. 4C), and circulating levels of total
cholesterol and HDLc were further elevated in dKO mice (Fig.
4D). IKBKE ablation also promoted increased liver mass (Fig.
3D) and histologically proven hepatic steatosis (Fig. S7A). Sim-
ilar findings were also observed in male mice (Fig. S8). Taken
together, these data demonstrate that IKBKE ablation in WD-
fed Apoe− /− mice enhanced hepatic expression of NLRP3
inflammasome-related genes, enhanced inflammation, enhanced
APR, and decreased cholesterol clearance. These features are
characteristic of increased hepatic metaflammation.
We next determined the effect of restoring hematopoietic IKBKE
on hepatic inflammasome priming and hepatic metaflammation. In
mice transplanted with Apoe−/− (Ikbke+/+) marrow, the expression of
hepatic Il1b, Nlrp3, Pycard, and Casp1 were all significantly reduced
(Fig. 4E). However, this reduction did not coincide with a general-
ized improvement in inflammation or macrophage infiltration.
Global M1/M2 inflammatory profiles and immune cell markers also
remained similar (Fig. 4F and Fig. S7 C and D). Nonetheless, he-
patic expression of the class 1 APPs Saa1 and Cxcl1 was reduced
(Fig. 4G), suggesting that these APPs may be more sensitive to
changes in IL-1β expression and reduced NLRP3 inflammasome
activity. Furthermore, the repression of Cyp7a1 was prevented, and
circulating cholesterol levels (TChol and HDLc) were reduced (Fig.
4 G and H), indicating improved cholesterol clearance. Taken to-
gether, these data strongly suggest that in this hyperlipidemic model,
hematopoietic IKBKE limits hepatic inflammasome priming, he-
patic acute phase response, and cholesterol catabolism.
IKBKE Deficiency and Hematopoietic Restoration Alters Atherosclerotic
Lesion Composition. Our observations demonstrate that IKBKE
ablation in Apoe−/−mice enhanced NLRP3 inflammasome priming,
metaflammation, adiposity, hepatosteatosis, APR, and hypercho-
lesterolemia, all of which are proatherogenic risk factors. Since
IKBKE is also present in atherosclerotic plaques, we reasoned that
IKBKE ablation might also promote atherosclerosis and that re-
constitution with hematopoietic IKBKE might elicit beneficial
Fig. 3. Effects of global IKBKE deficiency and he-
matopoietic restoration on inflammasome-related
gene expression and metaflammation in adipose
tissue. Apoe−/− and dKO mice (A–E), and dKO mice
(F–J) transplanted with either dKO BM (white) or
Apoe−/− BM (gray), were fed a WD for 16 wk before
sacrifice and tissue collection. Adipose tissue ex-
pression of NLRP3 inflammasome-related genes (A
and F), macrophage markers (Emr1, Itgam, and
Itgax), and adipokines (Lep and Tnf) (B and G).
(C and H) Histological sections of Epididymal WAT
(eWAT) stained with anti-EMR1. (Scale bars: 100
μm.) (D and I) Plasma leptin levels. (E and J) Weights
of Interscapular brown adipose tissue (BAT), In-
guinal s.c. white adipose tissue (scWAT), eWAT,
Retroperitoneal WAT (RpWAT), and liver. All data
are means ± SE (n = 5–9 per group). Statistical sig-
nificance is indicted by * or § P < 0.05, ** or §§ P <
0.01 and *** or §§§ P < 0.001 relative to Apoe−/−
mice (*) or dKO BM > dKO mice (§).





















effects. To test this hypothesis, we investigated the impact of both
global IKBKE ablation and reconstitution with hematopoietic
IKBKE on atherosclerotic plaque morphology and composition in
the same mice. Following 16 wk of WD feeding, all female Apoe−/−
mice had advanced lesions. However, IKBKE ablation did not
impact on plaque size, macrophage area, or SMA+ area, although
necrotic core sizes were smaller in dKO mice (Table 2). Following
restoration of IKBKE in hematopoietic cells, plaque sizes and
macrophage areas remained similar but plaque composition was
markedly altered. Apoe−/− BM mice had lesions with significantly
larger necrotic cores, an increased number of TUNEL-positive cells,
and a reduced SMA+ area (Table 2). Collectively, these features
may indicate changes in plaque stability and contrast with im-
provements in proatherogenic metabolic risk factors in these mice.
Nonetheless, in advanced atherosclerotic lesions, hematopoietic
IKBKE can influence local vascular remodeling.
Discussion
Great strides have been made in understanding how inflammation
is induced in immune cells and its defining role in inflammatory
diseases. In contrast, little is known about the cell-autonomous
mechanisms that govern the tone and chronicity of meta-
flammation. In this study we show that IKBKE, a downstream
mediator of TLR and cytokine signals, plays important dual roles in
regulating the tone and temporal kinetics of inflammation. It does
so through counterregulation of key stress-response genes involved
in NLRP3 inflammasome priming. This conclusion is supported by
three key findings: First, IKBKE is induced in parallel with genes
that prime the NLRP3 inflammasome in PRR-stimulated
macrophages. Second, the absence of IKBKE results in both en-
hanced and prolonged expression of Nlrp3, Il1a, and Il1b in
stimulated proinflammatory macrophages. Third, in WD-fed Apoe−/−
mice, in which multiple endogenous inflammasome activators are
generated, IKBKE ablation results in enhanced expression of
inflammasome-related genes and exacerbated metaflammation.
The pathological relevance of these findings is supported by the
fact that IKBKE is aberrantly expressed in three distinct human
tissues associated with metaflammation: i.e., in adipose tissue from
obese subjects, in livers of obese subjects with NASH, and in ath-
erosclerotic plaques where it also colocalized withmacrophages. The
specific role of hematopoietic IKBKE was confirmed in bone mar-
row transplant studies wherein wild-type IKBKE in hematopoietic
cells alone was sufficient to rescue the exacerbated adiposity, meta-
flammation, hyperinsulinemia, APR, and hypercholesterolemia.
Unexpectedly, IKBKE ablation and reconstitution with hemato-
poietic IKBKE does not alter the size of advanced atherosclerotic
lesions, rather it influences atherosclerotic plaque composition.
Chronic inflammation in the vasculature is a hallmark of
atherosclerotic plaques and is implicated in promoting plaque
development (in early plaques) and instability (in clinically rel-
evant advanced plaques). However, the requirement for NLRP3
inflammasome activity in atherosclerosis is hotly debated and
contrasting findings have been reported (13, 29). Recent studies
have also revealed additional complexities, suggesting IL-1R
signaling is beneficial and promotes plaque stability in advanced
atherosclerosis (30). Our studies show that IKBKE ablation in
Apoe−/− female mice further enhances proatherogenic metabolic
profiles and has minor effects on plaque composition. Although
hematopoietic IKBKE rescues the systemic metabolic features,
these improvements do not translate into an advantageous
plaque composition. This finding reinforces the notion that tissue
localized hematopoietic signals can override systemic metabolic
cues and highlights a potential to uncouple the pathological as-
sociation between metabolic features and atherosclerosis.
The observation that IKBKE ablation can promote obesity in
female mice contrasts with previous studies, which were all
performed in male mice (23–25). Although our study is not
Fig. 4. Effects of global IKBKE deficiency and he-
matopoietic restoration on hepatic inflammasome-
related gene expression and metaflammation. Ex-
perimental conditions were as described for Fig. 3.
Hepatic transcript expression was determined for
NLRP3 inflammasome-related genes (A and E ),
proinflammatory and macrophage marker genes (B
and F), and acute phase response genes (C and G).
(D and H) Plasma HDL cholesterol and total choles-
terol levels. All data are means ± SE (n = 5–9 per
group). Statistical significance is indicted by * or § P <
0.05, ** or §§ P < 0.01 and *** or §§§ P < 0.001 rel-
ative to Apoe−/− mice (*) or dKO BM > dKO mice (§).
Table 2. Effects of global IKBKE deficiency and hematopoietic restoration on atherosclerotic
plaque morphology and composition
Study 1 Study 2
Measurement Apoe−/− dKO dKO BM Apoe−/− BM
Lesion area (× 103 μm2) 275.3 ± 13.3 255.9 ± 9.5 199.1 ± 16.8 231.3 ± 15.6
Mac3 + ve area, % 13.3 ± 0.8 13.0 ± 2.0 21.3 ± 2.0 21.5 ± 2.1
SMA + ve area, % 21.0 ± 2.2 19.8 ± 1.5 28.7 ± 1.2 23.1 ± 1.0†
Necrotic area (× 103 μm2) 127.6 ± 8.7 99.4 ± 7.2* 53.5 ± 7.2 89.9 ± 13.0*
Tunnel + ve cells (no. per mm2) 30.9 ± 6.0 26.1 ± 4.5 69.7 ± 9.2 190.1 ± 12.0‡
Statistical significance is indicated (*P < 0.05; †P < 0.01; ‡P < 0.001) relative to study-specific control mice.
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directly comparable (owing to model-specific differences in
genotypes, sex, diet, and housing), we also performed parallel
studies in male littermates. Here, we reproduced a lack of effect
of IKBKE ablation on diet-induced adiposity in Apoe−/− mice.
This finding suggests that the functions of IKBKE in energy
balance are influenced by sex and warrants further investigation.
Whether sex dimorphism also plays a role in metabolic stress and
inflammasome activation remains to be formally addressed.
However, in the present study, the impact of IKBKE ablation on
NLRP3 inflammasome priming occurs in both genders.
In conclusion, this study demonstrates that IKBKE is relevant to
clinical pathologies that are associated with metaflammation. It is
induced by inflammatory signals in tissue macrophages where it
functions as a brake to limit the chronicity of NLRP3 inflamma-
some priming and subsequent inflammatory response. Whereas
global IKBKE deficiency in a disease model results in enhanced and
prolonged inflammasome priming and metaflammation, restoring
hematopoietic IKBKE is sufficient to rescue these features. These
findings provide new molecular insights into how innate immunity
may be self-regulated during low-grade chronic inflammation.
Moreover, the possibility that hematopoietic IKBKE may play
a nonpathogenic role in metaflammation is an important consid-
eration for therapeutic strategies aimed at treating metabolic dis-
eases such as NAFLD, obesity-related diabetes, and atherosclerosis.
Materials and Methods
Human Studies. Adipose tissue (scWAT) biopsies were collected during bariatric
surgery from female patients with a range of body mass indices (BMI) as re-
ported (31). The institutional review board at Indiana University approved all
protocols and patient consent was given. For liver biopsies, morbidly obese
patients undergoing bariatric surgery gave their informed written consent to
participate in this study in accordance with French legislation regarding ethics
and human research (Huriet-Serusclat law). The “Comité Consultatif de Pro-
tection des Personnes dans la Recherche Biomédicale de Nice” approved the
study (07/04:2003, N° 03.017). See SI Materials and Methods for additional
details and Table S1 for characteristics of the study groups.
Murine Studies. High fat diet fed C57BL/6 and ob/ob mice were generated and
treated as described (32). Apoe−/− (Apoetm1Unc × N10 onto C57BL/6 background)
mice were from Jackson Laboratories. Ikbke−/−(Ikbketm1Aki) mice were gener-
ated as reported (20). The UK Home Office and University of Cambridge ap-
proved all animal procedures. See SI Materials and Methods for additional
experimental details.
BMDM Studies. Bone marrow cells (BMCs) were collected from tibia of 11- to
13-wk-old female mice and treated in vitro as described in SI Materials and
Methods. Western blotting details are also described in SI Materials andMethods.
Targeted Gene Expression Profiling by Quantitative RT-PCR. Total RNA was
isolated by using STAT60 for tissues samples, and RNAeasy kits (Qiagen) for
BMDMs, according to the manufacturers’ instructions. Total RNA (500 ng)
was reverse-transcribed by using standard protocols. See SI Materials and
Methods for further details.
Statistical Analysis. Statistical analysis used two-tailed unpaired Student’s
t tests with P < 0.05 considered significant, with § or * for P < 0.05, §§ or **
for P < 0.01, and §§§ or *** for P < 0.001. Clinical correlations were analyzed
by using the Spearman’s rank correlation test.
ACKNOWLEDGMENTS. We thank Gökhan Hotamisligil for critical reading of
the manuscript and acknowledge excellent technical assistance from C. Marciano,
A. Superville, L. Baker, J. Harrison, M. Dale, A. Lukasik, and core facilities
staff at University of Cambridge Central Biomedical Services, Medical Research
Council Centre for Obesity and Related Metabolic Diseases (MRC-CORD) Phe-
nomics Centre, MRC-CORD Biochemistry Lab and MRC-CORD Microscopy and
Histology Labs. Funding was provided by a British Heart Foundation Project
Grant PG/10/38/28359 (to J.K.S.), a PhD Studentship (to W.G.B.), and in part by
Programme Grants RG/12/13/29853 (to A.V.-P.) and RG/13/14/30314 (to M.R.B.);
Gates Cambridge PhD Scholarship (to M.N.P.); a Wellcome Trust PhD Student-
ship (to N.B.M.); and the National Institute for Health Research Cambridge Bio-
medical Research Centre. Clinical hepatic studies were funded by INSERM, the
University of Nice, the Programme Hospitalier de Recherche Clinique (Centre
Hospitalier Universitaire of Nice), a European Foundation for the Study of Di-
abetes/Lilly Fellowship (to P.G.), and the French Government (National Research
Agency) through “Investments for the Future” LABEX SIGNALIFE Grant ANR-11-
LABX-0028-01.
1. Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell
140(6):805–820.
2. Kawai T, Akira S (2009) The roles of TLRs, RLRs and NLRs in pathogen recognition. Int
Immunol 21(4):317–337.
3. Könner AC, Brüning JC (2011) Toll-like receptors: Linking inflammation to metabo-
lism. Trends Endocrinol Metab 22(1):16–23.
4. Shi H, et al. (2006) TLR4 links innate immunity and fatty acid-induced insulin re-
sistance. J Clin Invest 116(11):3015–3025.
5. Rivera CA, et al. (2007) Toll-like receptor-4 signaling and Kupffer cells play pivotal
roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 47(4):571–579.
6. Miura K, et al. (2010) Toll-like receptor 9 promotes steatohepatitis by induction of
interleukin-1beta in mice. Gastroenterology 139(1):323–334, e7.
7. Cook DN, Pisetsky DS, Schwartz DA (2004) Toll-like receptors in the pathogenesis of
human disease. Nat Immunol 5(10):975–979.
8. Frantz S, Ertl G, Bauersachs J (2007) Mechanisms of disease: Toll-like receptors in
cardiovascular disease. Nat Clin Pract Cardiovasc Med 4(8):444–454.
9. Weatherill AR, et al. (2005) Saturated and polyunsaturated fatty acids reciprocally mod-
ulate dendritic cell functions mediated through TLR4. J Immunol 174(9):5390–5397.
10. Jimenez-Dalmaroni MJ, et al. (2009) Soluble CD36 ectodomain binds negatively charged
diacylglycerol ligands and acts as a co-receptor for TLR2. PLoS ONE 4(10):e7411.
11. Stienstra R, et al. (2011) Inflammasome is a central player in the induction of obesity
and insulin resistance. Proc Natl Acad Sci USA 108(37):15324–15329.
12. Kanneganti TD, Dixit VD (2012) Immunological complications of obesity. Nat Immunol
13(8):707–712.
13. Duewell P, et al. (2010) NLRP3 inflammasomes are required for atherogenesis and
activated by cholesterol crystals. Nature 464(7293):1357–1361.
14. Rajamäki K, et al. (2010) Cholesterol crystals activate the NLRP3 inflammasome in
human macrophages: A novel link between cholesterol metabolism and inflammation.
PLoS ONE 5(7):e11765.
15. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1
family. Annu Rev Immunol 27:519–550.
16. Keller M, Rüegg A, Werner S, Beer HD (2008) Active caspase-1 is a regulator of un-
conventional protein secretion. Cell 132(5):818–831.
17. Labbe K, Saleh M (2011) Pyroptosis: A caspase-1-dependent programmed cell death and
a barrier to infection. Progress in Inflammation Research, ed Couilin I (Springer, Basel),
pp 18–36.
18. Sharma S, et al. (2003) Triggering the interferon antiviral response through an IKK-
related pathway. Science 300(5622):1148–1151.
19. tenOever BR, et al. (2004) Activation of TBK1 and IKKvarepsilon kinases by vesicular
stomatitis virus infection and the role of viral ribonucleoprotein in the development
of interferon antiviral immunity. J Virol 78(19):10636–10649.
20. Hemmi H, et al. (2004) The roles of two IkappaB kinase-related kinases in lipopoly-
saccharide and double stranded RNA signaling and viral infection. J Exp Med 199(12):
1641–1650.
21. Fitzgerald KA, et al. (2003) IKKepsilon and TBK1 are essential components of the IRF3
signaling pathway. Nat Immunol 4(5):491–496.
22. Boehm JS, et al. (2007) Integrative genomic approaches identify IKBKE as a breast
cancer oncogene. Cell 129(6):1065–1079.
23. Chiang SH, et al. (2009) The protein kinase IKKepsilon regulates energy balance in
obese mice. Cell 138(5):961–975.
24. Reilly SM, et al. (2013) An inhibitor of the protein kinases TBK1 and IKK-e improves
obesity-related metabolic dysfunctions in mice. Nat Med 19(3):313–321.
25. Scheja L, Heese B, Seedorf K (2011) Beneficial effects of IKKe-deficiency on body
weight and insulin sensitivity are lost in high fat diet-induced obesity in mice. Bio-
chem Biophys Res Commun 407(2):288–294.
26. Lohmann C, et al. (2009) Atherosclerotic mice exhibit systemic inflammation in peri-
adventitial and visceral adipose tissue, liver, and pancreatic islets. Atherosclerosis
207(2):360–367.
27. Bartelt A, et al. (2011) Altered endocannabinoid signalling after a high-fat diet in
Apoe(-/-) mice: relevance to adipose tissue inflammation, hepatic steatosis and insulin
resistance. Diabetologia 54(11):2900–2910.
28. Sheedy FJ, et al. (2013) CD36 coordinates NLRP3 inflammasome activation by facili-
tating intracellular nucleation of soluble ligands into particulate ligands in sterile
inflammation. Nat Immunol 14(8):812–820.
29. Menu P, et al. (2011) Atherosclerosis in ApoE-deficient mice progresses independently
of the NLRP3 inflammasome. Cell Death Dis 2:e137.
30. Alexander MR, et al. (2012) Genetic inactivation of IL-1 signaling enhances athero-
sclerotic plaque instability and reduces outward vessel remodeling in advanced ath-
erosclerosis in mice. J Clin Invest 122(1):70–79.
31. Carobbio S, et al. (2013) Adaptive changes of the Insig1/SREBP1/SCD1 set point help adi-
pose tissue to cope with increased storage demands of obesity. Diabetes 62(11):3697–3708.
32. Lagathu C, et al. (2009) Dact1, a nutritionally regulated preadipocyte gene, controls
adipogenesis by coordinating the Wnt/beta-catenin signaling network. Diabetes
58(3):609–619.
33. Prieur X, et al. (2011) Differential lipid partitioning between adipocytes and tissue
macrophages modulates macrophage lipotoxicity and M2/M1 polarization in
obese mice. Diabetes 60(3):797–809.
Patel et al. PNAS | January 13, 2015 | vol. 112 | no. 2 | 511
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
